본문 바로가기
KERD
논문KCI 등재

Recent advances in Toxoplasma gondii immunotherapeutics

Sherene Swee-Yin Lim|Rofina Yasmin Othman
대한기생충학ㆍ열대의학회 (The Korean Society For Parasitology and Tropical Medicine)|2014.12|Parasites, Hosts and Diseases|제52권 제6호|pp. 581-593|DOI 10.3347/kjp.2014.52.6.581

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

vaccinepassive immunizationToxoplasma gondiiimmunotherapeutics
주제분류예방의학/직업환경의학

초록

Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.

Abstract

Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.

참고문헌 (91)

  1. Chowdhury M, "Toxoplasmosis : a review", J Med, 17, pp.373~396 (1986)
  2. Brindle R, "Toxoplasma antibodies in HIV-positive patients from Nairobi", Trans R Soc Trop Med Hyg, 85, pp.750~751 (1991)
  3. Mui EJ, "Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo", PLoS Negl Trop Dis, 2, pp.190~ (2008)
  4. Khan A, "Genetic Divergence of Toxoplasma gondii Strains Associated with Ocular Toxoplasmosis, Brazil", Emerg Infect Dis, 12, pp.942~949 (2006)
  5. Bottos J, "Bilateral retinochoroiditis caused by an atypical strain of Toxoplasma gondii", Br J Ophthalmol, 93, pp.1546~1550 (2009)
  6. Garcia J, "Current progress toward vaccines against Toxoplasma gondii", Vaccine Devel Ther, 4, pp.23~37 (2014)
  7. Kur J, "Current status of toxoplasmosis vaccine development", Expert Rev Vaccines, 8, pp.791~808 (2009)
  8. Tan TG, "Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans", Vaccine, 28, pp.3977~3989 (2010)
  9. Gazzinelli RT, "Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine", J Immunol, 146, pp.286~292 (1991)
  10. Brown CR, "Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection", J Immunol, 145, pp.3438~3441 (1990)
  11. Jongert E, "Vaccines against Toxoplasma gondii : challenges and opportunities", Mem Inst Oswaldo Cruz, 104, pp.252~266 (2009)
  12. Debard N, "Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection", Infect Immun, 64, pp.2158~2166 (1996)
  13. Khan IA, "A purified parasite antigen(p30)mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice", J Immunol, 147, pp.3501~3506 (1991)
  14. Bonenfant C, "Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii", Infect Immun, 69, pp.1605~1612 (2001)
  15. Qu D, "Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re", Exp Parasitol, 135, pp.234~239 (2013)
  16. Letscher-Bru V, "Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB", c mice but not in CBA, Infect Immun, pp.2003, 71[DOI]
  17. Chuang SC, "Induction of long-lasting protective immunity against Toxoplasma gondii in BALB", c mice by recombinant surface antigen 1 protein encapsulated in poly(lactide-co-glycolide)microparticles, 2013, pp.6, 34~
  18. Chuang SC, "Encapsulation of chimeric protein rSAG1", 2 into poly(lactide-co-glycolide)microparticles induces long-term protective immunity against Toxoplasma gondii in mice, 2013, pp.134, 430~437
  19. Yin LT, "Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against Toxoplasmosis", PLoS ONE, 8, pp.e82765~ (2013)
  20. Wang HL, "Intranasal immunisation of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii infection", Acta Trop, 137, pp.58~66 (2014)
  21. Nakaar V, "Pleiotropic effect due to targeted depletion of secretory rhoptry protein ROP2 in Toxoplasma gondii", J Cell Sci, 116, pp.2311~2320 (2003)
  22. 남호우, "GRA Proteins of Toxoplasma gondii: Maintenance of Host-Parasite Interactions across the Parasitophorous Vacuolar Membrane", The Korean Journal of Parasitology, 47, pp.29~37 (2009), 대한기생충학ㆍ열대의학회
  23. Martin V, "Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis", Clin Diagn Lab Immunol, 11, pp.704~710 (2004)
  24. Dziadek B, "Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis", Vaccine, 29, pp.821~830 (2011)
  25. Dziadek B, "Toxoplasma gondii : the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB", c mice, 2012, pp.131, 133~138
  26. El Bissati K, "Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice", Vaccine, 32, pp.3243~3248 (2014)
  27. del L. Yácono M, "A chloroplast-derived Toxoplasma gondii GRA4 antigen used as an oral vaccine protects against toxoplasmosis in mice", Plant Biotechnol J, 10, pp.1136~1144 (2012)
  28. Laguia-Becher M, "Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice", BMC Biotechnol, 10, pp.52~ (2010)
  29. Zheng B, "The virulence-related rhoptry protein 5(ROP5)of Toxoplasmag gondii is a novel vaccine candidate against toxoplasmosis in mice", Vaccine, 31, pp.4578~4584 (2013)
  30. Sanchez VR, "Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection", Exp Parasitol, 128, pp.448~453 (2011)
  31. Wang Y, "Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens", Vaccine, 29, pp.8619~8623 (2011)
  32. Wang HL, "Toxoplasma gondii Protein Disulfide Isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis", PLoS ONE, 8, pp.e70884~ (2013)
  33. Zhang NZ, "Evaluation of immune responses in mice after DNA immunization with putative Toxoplasma gondii Calcium-Dependent Protein Kinase 5(TgCDPK5)", Clin Vaccine Immunol, 21, pp.924~929 (2014)
  34. Yuan ZG, "Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model", Vaccine, 31, pp.3135~3139 (2013)
  35. Chen J, "Toxoplasma gondii : protective immunity induced by rhoptry protein 9(TgROP9)against acute toxoplasmosis", Exp Parasitol, 139, pp.42~48 (2014)
  36. Chen J, "Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice", Vaccine, 31, pp.1734~1739 (2013)
  37. Liu Q, "Vaccines against Toxoplasma gondii : status, challenges and future directions", Hum Vaccines Immunother, 8, pp.1305~1308 (2012)
  38. Saade F, "Technologies for enhanced efficacy of DNA vaccines", Expert Rev Vaccines, 11, pp.189~209 (2012)
  39. Beghetto E, "A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts", J Infect Dis, 191, pp.637~645 (2005)
  40. Henriquez FL, "Immunogenetics of Toxoplasma gondii informs vaccine design", Trends Parasitol, 26, pp.550~555 (2010)
  41. Kessler H, "Microneme protein 8-a new essential invasion factor in Toxoplasma gondii", J Cell Sci, 121, pp.947~956 (2008)
  42. Liu MM, "Toxoplasma gondii microneme protein 8(MIC8)is a potential vaccine candidate against toxoplasmosis", Parasitol Res, 106, pp.1079~1084 (2010)
  43. Li ZY, "Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice", Vaccine, 32, pp.3058~3065 (2014)
  44. Nielsen HV, "Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene", Infect Immun, 67, pp.6358~6363 (1999)
  45. Petersen E, "Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii", Vaccine, 16, pp.1283~1289 (1998)
  46. Cong H, "Compound DNA vaccine encoding SAG1", SAG3 with A2, c mice against Toxoplasma gondii, pp.Parasit Vectors, 2013[DOI]
  47. Meng M, "Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1(SAG1)and 14-3-3 protein in BALB", c mice, 2012, pp.5, 273~
  48. Zhou H, "Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant", Vaccine, 30, pp.1800~1806 (2012)
  49. Liu S, "Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice", Parasitol Res, 105, pp.267~274 (2009)
  50. Fachado A, "Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice", Vaccine, 21, pp.1327~1335 (2003)
  51. Ivory C, "DNA vaccines : designing strategies against parasitic infections", Genet Vaccines Ther, 2, pp.17~ (2004)
  52. Parthasarathy S, "Protective immune response in BALB", c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii, 2013, pp.88, 883~887
  53. Gong P, "The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB", c mice, 2013, pp.35, 140~146
  54. Sun XM, "DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB", c mice, 2011, pp.4, 213~
  55. Wang PY, "Protective efficacy of a Toxoplasma gondii Rhoptry Protein 13 plasmid DNA vaccine in mice", Clin Vaccine Immunol, 19, pp.1916~1920 (2012)
  56. Yuan ZG, "Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice", Clin Vaccine Immunol, 18, pp.119~124 (2011)
  57. Yuan ZG, "Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18", Vaccine, 29, pp.6614~6619 (2011)
  58. Li J, "Toxoplasma gondii rhomboid protein 1(TgROM1)is a potential vaccine candidate against toxoplasmosis", Vet Parasitol, 184, pp.154~160 (2012)
  59. Yan HK, "Toxoplasma gondii : protective immunity against experimental toxoplasmosis induced by a DNA vaccine encoding the perforin-like protein 1", Exp Parasitol, 128, pp.38~43 (2011)
  60. Zhang NZ, "Protective immunity against Toxoplasma gondii induced by DNA immunization with the gene encoding a novel vaccine candidate : calcium-dependent protein kinase 3", BMC Infect Dis, 13, pp.512~ (2013)
  61. Zhang M, "DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB", c mice against type II parasite infection, 2013, pp.31, 4536~4540
  62. Yu L, "Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice", Parasitol Int, 61, pp.481~486 (2012)
  63. Meng M, "DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB", c mice, 2013, pp.13, 494~
  64. Zhao H, "Evaluation on the immune response induced by DNA vaccine encoding MIC8 co-immunized with IL-12 genetic adjuvant against Toxoplasma gondii infection", Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi(Chinese J Parasitol Parasit Dis), 31, pp.284~289 (2013)
  65. Chen J, "DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice", Vaccine, 31, pp.6225~6231 (2013)
  66. Cui X, "Toxoplasma gondii immune mapped protein-1(TgIMP1)is a novel vaccine candidate against toxoplasmosis", Vaccine, 30, pp.2282~2287 (2012)
  67. Zhang G, "A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice", Parasitology, 134, pp.1339~1346 (2007)
  68. Taylor DN, "Evaluation of a bivalent(CVD 103-HgR", CVD 111)live oral cholera vaccine in adult volunteers from the United States and Peru, 1997, pp.65, 3852~3856
  69. Virnik K, "Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques", Retrovirology, 10, pp.99~ (2013)
  70. Toussaint B, "Live-attenuated bacteria as a cancer vaccine vector", Expert Rev Vaccines, 12, pp.1139~1154 (2013)
  71. Detmer A, "Live bacterial vaccines-a review and identification of potential hazards", Microb Cell Fact, 5, pp.23~ (2006)
  72. Mendes ÉA, "Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1", PLoS One, 8, pp.e63201~ (2013)
  73. Cong H, "Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii", Parasite Immunol, 27, pp.29~35 (2005)
  74. Liu Q, "A recombinant pseudorabies virus expressing TgSAG1 protects against challenge with the virulent Toxoplasma gondii RH strain and pseudorabies in BALB", c mice, 2008, pp.10, 1355~1362
  75. Nie H, "Immunogenicity and protective efficacy of two recombinant pseudorabies viruses expressing Toxoplasma gondii SAG1 and MIC3 proteins", Vet Parasitol, 181, pp.215~221 (2011)
  76. Mack DG, "HLA-class II genes modify outcome of Toxoplasma gondii infection", Int J Parasitol, 29, pp.1351~1358 (1999)
  77. Suzuki Y, "Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients", J Infect Dis, 173, pp.265~268 (1996)
  78. Dubey JP, "Oral oocyst-induced mouse model of toxoplasmosis : effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains(transgenic, out-bred, in-bred)on pathogenesis and mortality", Parasitology, 139, pp.1~13 (2012)
  79. Bruna-Romero O, "Current Topics in Tropical Medicine" (2012), InTech
  80. Yarovinsky F, "Innate immunity to Toxoplasma gondii infection", Nat Rev Immunol, 14, pp.109~121 (2014)
  81. Beghetto E, "Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries", Int J Parasitol, 33, pp.163~173 (2003)
  82. Bhadra R, "The CD8 T-cell road to immunotherapy of toxoplasmosis", Immunotherapy, 3, pp.789~801 (2011)
  83. Bhadra R, "Donor CD8+ T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8+ T cell population", Infect Immun, 81, pp.3414~3425 (2013)
  84. Kang H, "Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase", J Immunol, 164, pp.2629~2634 (2000)
  85. Sayles PC, "B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii", Infect Immun, 68, pp.1026~1033 (2000)
  86. Johnson LL, "Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice", Infect Immun, 70, pp.185~191 (2002)
  87. Fu YF, "Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites", Infect Immun, 79, pp.512~517 (2011)
  88. Cha DY, "Effects of specific monoclonal antibodies to dense granular proteins on the invasion of Toxoplasma gondii in vitro and in vivo", Korean J Parasitol, 39, pp.233~240 (2001)
  89. Tan F, "Monoclonal antibodies against nucleoside triphosphate hydrolase-II can reduce the replication of Toxoplasma gondii", Parasitol Int, 59, pp.141~146 (2010)
  90. Ferreira à Jr, "Production, characterization and applications for Toxoplasma gondii-specific polyclonal chicken egg yolk immunoglobulins", PLoS ONE, 7, pp.e40391~ (2012)
  91. Larsson A, "Chicken antibodies : taking advantage of evolution-a review", Poult Sci, 72, pp.1807~1812 (1993)

관련 논문AI추천

Recent progress in vaccine development targeting pre-clinical human toxoplasmosis전복실, 주기백대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2023 · 제61권 제3호Immune Responses Induced by HSP60 DNA Vaccine against Toxoplasma gondii Infection in Kunming MiceJia Chen, Jing Lu, Nian-Zhang Zhang, Xing-Quan Zhu, Zhong-Yuan Li대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2018 · 제56권 제3호DNA Vaccines Encoding Toxoplasma gondii Cathepsin C 1 Induce Protection against Toxoplasmosis in MiceAihua Zhou, Gang Lu, Guang-Hui Zhao, Hua Cong, Huaiyu Zhou, Jian Zhou, Jingjing Guo, Lin Wang, Shenyi He, Wenchao Sha, Yali Han대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2017 · 제55권 제5호Evaluation of Protective Immune Response Induced by a DNA Vaccine Encoding GRA8 against Acute Toxoplasmosis in a Murine Model이영하, Cai-Yuan Yu, Jia-Qi Chu, Juan-Hua Quan, Rui Huang, Shi-Cai Ye, Shuai Huang, Wei Ye, Wei-Yun Wu, Wei Zhou, Xuan-Yan Fan, Yu Zhou대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2018 · 제56권 제4호Virus-like Particle Vaccine Containing Toxoplasma gondii Rhoptry Protein 13 Induces Protection against T. gondii ME49 Infection in Mice강해지, 김민주, 박현우, Fu-Shi Quan, Hui Jin, Ki-Back Chu, Su-Hwa Lee대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2019 · 제57권 제5호Virus-Like Particles Expressing Toxoplasma gondii Rhoptry Protein 18 Induces Better Protection Than Rhoptry Protein 4 against T. gondii Infection강해지, 이동훈, 이수화, 추기백, Fu Shi Quan대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2018 · 제56권 제5호

이 간행물의 다른 논문 (17건)

Trichomonas vaginalis metalloproteinase induces mTOR cleavage of SiHa cells양정보, Wei Zhou, 류재숙, Yu Zhou, 차광호, 최인욱, 이영하, Juan-Hua Quanpp. 595-603Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatmentChun-Feng Xin, 신은희, 채종일, 정봉광, 표경호pp. 605-612Flavonoids modulate the proliferation of Neospora caninum in glial cell primary culturesSilvia Lima Costapp. 613-619Prevalence and clinical manifestations of malaria in Aligarh, IndiaAsma, Umm-epp. 621-629Plasmodium falciparum genotype diversity in artemisinin derivatives treatment failure patients along the Thai-Myanmar borderCongpuong, Kanungnitpp. 631-637
원문 보기